Author of

• 18972

  +

  P2.02 - Biology/Pathology (ID 616)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23231

    +

    P2.02-033 - The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma (ID 8842)

    09:30 - 09:30  |  Presenting Author(s): Jinghui Wang
    • Abstract

    Background:
    Programmed cell death-1 (PD-1) inhibitor is one of important medicines of immunotherapy for cancers. Programmed cell death ligand-1 (PD-L1) expression is a valuable predictor for selection of patients by PD-1 inhibitors therapy. However, the correlation of PD-L1 expression with clinicopathologic features, EGFR and ALK status, and prognosis of lung adenocarcinoma remain controversial.
    
    Method:
    421 lung adenocarcinoma patients with identified EGFR and ALK status in tumor tissues were enrolled. Using tissue microarrays, PD-L1 expression was evaluated using clone SP263 antibody by immunohistochemistry (IHC) on Ventana Benchmark automated staining system. The association of PD-L1 expression with clinicopathologic characteristics, EGFR and ALK status and prognosis of lung adenocarcinoma were analysed.
    
    Result:
    A total of 404 patients were available for evaluation. The positve incidence of PD-L1 expression was 22.5% (91/404) (using a cutoff of ≥ 25%). Multivariate Logistic regression analysis showed PD-L1 expression was associated with advanced stage (ORR 2.190, 95% CI 1.313-3.651, P = 0.003), solid predominant subtype (ORR 3.594, 95% CI 1.826-7.073, P < 0.001), and wild-type epidermal growth factor receptor (EGFR) (ORR 1.895, 95% CI 1.091-3.291, P = 0.023), while it was not associated with ALK rearrangement. In multivariate analysis for OS by Cox hazard proportion model, patients with early stage (HR 2.495, 95% CI 2.003-3.106, P < 0.001) and EGFR mutations (HR 1.635, 95% CI 1.310-2.040, P < 0.001) had a significantly longer survival, while PD-L1 expression was not associated with OS of patients with lung adenocarcinoma (HR 0.847, 95% CI 0.655-1.094, P = 0.203).
    
    Conclusion:
    Positive PD-L1 expression in lung adenocarcinoma tissues was significantly associated with tumor advanced stage, solid predominant subtype, and wild-type EGFR, however, PD-L1 expression may not be a predictor of OS for patients with lung adenocarcinoma.